TOMI Environmental Solutions, a global company specialising in disinfection and decontamination solutions, has announced that a US-based multinational pharmaceutical company is expanding the use of SteraMist decontamination products, advancing SteraMist as this pharmaceutical company’s decontamination standard.
The company originally began using SteraMist Environment Systems 5 years ago to disinfect and decontaminate small spaces in their animal health division.
Our industry is seeing tremendous interest and activity amidst a variety of new vaccine breakthroughs, drug research, and strength in the bioeconomy, and companies are accelerating their investments in disinfection and decontamination stay ahead of the competition
Since their initial purchase, the company has ordered multiple additional systems, including: three mobile units for a second animal health location 2 years ago, followed by a divisional location adding three SteraMist Environment Systems. This fiscal year, eight environment full-room foggers were added to other divisional locations, the purchase of two of these systems were ordered and delivered this quarter.
By the end of 2022, TOMI expects to complete the design and manufacturing of two CES’s for the company totalling approximately $1 million in value with recurring BIT Solution sales for these two systems expected to generate approximately $250,000 in revenue annually starting in 2023. A third CES has just received approval for their Delaware location.
“These purchases by one of our long-term existing customers are an indication of TOMI’s growing reputation as the standard for disinfection and decontamination in the life sciences industry,” Elissa J. (E.J.) Shane, COO of TOMI Environmental, said. “Our industry is seeing tremendous interest and activity amidst a variety of new vaccine breakthroughs, drug research, and strength in the bioeconomy, and companies are accelerating their investments in disinfection and decontamination stay ahead of the competition. We are pleased to provide our products to both existing and new partners and to play a large role in keeping the labs and facilities that produce our vaccines and medicines safe from potentially harmful contaminates.”
